Cardiovascular health in pediatric heart transplant patients

  • Carmel Bogle (Creator)
  • Amanda K Marma (Creator)
  • Sarah J. Wilkens (Creator)
  • Alaa Aljiffry (Creator)
  • Karen Rychlik (Creator)
  • John M. Costello (Medical University of South Carolina) (Creator)
  • Donald M Lloyd-Jones (Creator)
  • Elfriede Pahl (Creator)
  • John M. Costello (Creator)
  • Donald M. Lloyd-Jones (Creator)

Dataset

Description

Abstract Background Ideal “cardiovascular health” (CVH)–optimal diet, exercise, nonsmoking, BMI, BP, lipids, and glucose—is associated with healthy longevity in adults. Pediatric heart transplant (HT) patients may be at risk for suboptimal CVH. Methods Single-center retrospective study of HT patients 2003–2014 who survived 1 year post-transplant. Five CVH metrics were collected at listing, 1, 3 and 5 years post-transplant (diet and exercise were unavailable). CVH was scored by summing individual metrics: ideal = 2, intermediate = 1, and poor = 0 points; total scores of 8–10 points were considered high (favorable). CVH was compared between HT patients and the US pediatric population (GP) utilizing NHANES 2007–2016. Logistic regression was performed to examine the association of CVH 1 year post-transplant with a composite adverse outcome (death, re-listing, coronary vasculopathy, or chronic kidney disease) 3 years post-transplant. Results We included 110 HT patients (median age at HT: 6 years [range 0.1–21]) and 19,081 NHANES participants. CVH scores among HT patients were generally high at listing (75%), 1 (74%), 3 (87%) and 5 (76%) years post-transplant and similar to GP, but some metrics (e.g., glucose) were worse among HT patients. Among HT patients, CVH was poorer with older age and non-Caucasian race/ethnicity. Per 1-point higher CVH score, the demographic-adjusted OR for adverse outcomes was 0.95 (95% CI, 0.7–1.4). Conclusions HT patients had generally favorable CVH, but some metrics were unfavorable and CVH varied by age and race/ethnicity. No significant association was detected between CVH and adverse outcomes in this small sample, but study in a larger sample is warranted.
Date made available2022
Publisherfigshare

Cite this